The study compares a nutraceutical containing Tanacetum Parthenium (titled in parthenolide), 5-hydroxytryptophan (5-HTP) from Griffonia simplicifolia and magnesium (AuraSTOP®) compared to only Magnesium in the migraine aura and its evolution towards the painful phase.
Aura migraine is characterized by the appearance of focal and reversible neurological symptoms, more frequently visual, linked to the phenomenon of diffuse cortical depression (CSD), a temporary wave of alteration of cerebral electrical activity which spreads at the cortical level1.
Magnesium is known for its role in stabilizing neuronal membranes and reducing cortical hyperexcitability, while Tanacetum Parthenium exerts an anti-inflammatory and modulating action of neurovascular mediators.2. 5-HTP, a precursor of serotonin, contributes to the regulation of the serotonergic system, involved in the mechanisms of migraine3.
The main objective of the study was to evaluate whether AuraSTOP was more effective than magnesium alone in reducing the duration of the aura and in preventing or attenuating the subsequent head of the head. The included subjects took AuraSTOP and only magnesium at the onset of auratic symptoms, and parameters such as aura duration, subsequent headache intensity, need for symptomatic drugs and tolerability were evaluated.
The results show that the combination containing Tanacetum Parthenium, 5-HTP and magnesium is associated with a more marked reduction in the duration of the aura than magnesium alone. In addition, subjects who have used AuraSTOP are observed an increased probability of attenuation or failure to appear in the subsequent painful phase. However, magnesium alone shows a beneficial effect, but of a lower magnitude than when combined with other active ingredients.
The use of both nutraceuticals was generally well tolerated in both groups, without reporting serious unwanted events. The authors conclude that the association of the three components seems to exert a synergistic effect on the pathophysiological mechanisms of the migraine aura, suggesting that a multimodal approach may be more effective than monotherapy with magnesium.
However, the methodological limits related to the study design (observational or non-randomized) are underlined, which require additional controlled clinical trials to definitively confirm the superiority of the combination over magnesium alone in the treatment of the migraine aura.
- Costa C., et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain. 2013;14(1):62
- Wider B., et al. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;2015(4):CD002286.
- Brown B., et al. Migraine headaches: opportunities for management with precisione nutrition. Nutr. Med. J., 1(3):117-152.
(Dal Volta G., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy triptohan and magnesium (AuraSTOP) in the prevention of high frequency migraine with aura. Open Access Library. 2018;5,E4939)
(Mainardi F., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy tryptohan and magnesium (AuraSTOP) in Episodic migraine prevention: a multicentric Observational Study Open Access Library Journal 2018;5,E4765).
(Ferrare P., et A. Tanacetum, Parthenium, Griffonia simplicifolia and magnesium as symptomatic and prophylactic treatment for headache in Paediatric Patients. International Journal of Neurology and Braind Disorders ISSN 2377-1348).
(Zavarise P., et al. Combination of Tanacethum Partenium, 5-Hydroxitriptophan (5-HTTP) and Magnesium in the Prophylaxis of Episodic migraine without aura (Aurastop®) An observational study.

